Thus, accurate determination of HER2 status is critical to identify patients who could benefit from HER2-targeted therapies and to avoid ineffective treatment and unnecessary adverse effects in the management of breast cancer patients [4,5]. The gene discussed is ERBB2; the disease is breast carcinoma.